Nucleoside and nucleotide analogues inhibit HBV replication by competing with the natural nucleoside triphosphates for incorporation into viral DNA. Lamivudine and adefovir are the approved nucleoside ...

Bepirovirsen, an investigational antisense oligonucleotide, led to sustained virologic response and a sustained decrease in hepatitis B virus (HBV) DNA, without the need for rescue medication, in ...

MAUI, HAWAII – There might well be a cure for hepatitis B in coming years, just like there is now for hepatitis C, according to Norah Terrault, MD, chief of the division of GI and liver at the ...

HealthDay News — For sorafenib-treated patients with hepatitis B virus-related hepatocellular carcinoma, antiviral therapy with nucleoside analogues is associated with improved survival, according to ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Geneva, March 30, 2023 – More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with ...

A greater percentage of patients treated with tenofovir alafenamide achieved HBV DNA levels below 20 IU/mL at 24 weeks compared with placebo. The Food and Drug Administration (FDA) has expanded the ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has updated the label indication for 25 mg ...